SAM
BMRN icon

Smartleaf Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Smartleaf Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.4K Hold
1,325
– – ﹤0.01% 1293
2026
Q1 		$72.6K Buy
1,325
+614
+86% +$35.8K ﹤0.01% 1267
2025
Q4 		$41.9K Sell
711
-38
-5% -$2.07K ﹤0.01% 1639
2025
Q3 		$40.5K Buy
749
+360
+93% +$20.6K ﹤0.01% 1491
2025
Q2 		$21.5K Sell
389
-312
-45% -$18.4K ﹤0.01% 1518
2025
Q1 		$50.1K Sell
701
-184
-21% -$12.4K ﹤0.01% 1145
2024
Q4 		$57.9K Buy
885
+466
+111% +$31.2K 0.01% 1111
2024
Q3 		$29.6K Buy
419
+315
+303% +$26.3K ﹤0.01% 1127
2024
Q2 		$8.68K Buy
104
+94
+940% +$7.83K ﹤0.01% 1487
2024
Q1 		$886 Buy
+10
New +$895 ﹤0.01% 1643

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Smartleaf Asset Management's BMRN Position: Q2 2026 in Review

Smartleaf Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1,325 shares worth $76.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1293.

Smartleaf Asset Management first reported a position in BMRN in Q1 2024 and has held it in 10 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Smartleaf Asset Management held 1,325 shares of BioMarin Pharmaceuticals worth $76.4K as of Q2 2026.
  • Smartleaf Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1293 holding.
  • Smartleaf Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.